Gulati O P, Liard J F
Arch Int Pharmacodyn Ther. 1979 Aug;240(2):285-93.
Propranolol administered subcutaneously in a dise of 30 mg/kg twice a day for 3 weeks did not significantly lower systolic tail blood pressure (STBP) in chronic two-kidney Goldblatt hypertension in rats. Plasma renin activity (PRA) measured at the end of the treatment was not significantly different in propranolol treated and dextrose treated rats, although there was marked bradycardia in propranolol treated rats. However, 3 out of 10 propranolol treated hypertensive rats had pressures in the normotensive range during the last week of therapy. PRA values in these three rats were significantly lower than those in dextrose treated hypertensive rats. STBP on day 20 showed a positive correlation with PRA in both propranolol (r = 0.90, p less than 0.01) and dextrose (r = 0.85, p less than 0.01) treated hypertensive rats. Hypertension was associated with an increase in heart weight, which was significantly blunted but not abolished by propranolol treatment. Thus, propranolol did not decrease blood pressure in most rats with chronic two-kidney Goldblatt hypertension; when it did lower blood pressure, its antihypertensive effect appeared related to its renin suppression effect. Furthermore, propranolol mitigated hypertension induced cardiac hypertrophy, independently of its antihypertensive effect.
在大鼠慢性双肾 Goldblatt 高血压模型中,每天两次皮下注射 30 mg/kg 的普萘洛尔,持续 3 周,并未显著降低尾动脉收缩压(STBP)。治疗结束时测量的血浆肾素活性(PRA)在普萘洛尔治疗组和葡萄糖治疗组大鼠中无显著差异,尽管普萘洛尔治疗组大鼠出现明显心动过缓。然而,在治疗的最后一周,10 只接受普萘洛尔治疗的高血压大鼠中有 3 只血压处于正常范围。这三只大鼠的 PRA 值显著低于葡萄糖治疗的高血压大鼠。在普萘洛尔(r = 0.90,p < 0.01)和葡萄糖(r = 0.85,p < 0.01)治疗的高血压大鼠中,第 20 天的 STBP 与 PRA 呈正相关。高血压与心脏重量增加有关,普萘洛尔治疗可显著减轻但未消除这种增加。因此,普萘洛尔对大多数慢性双肾 Goldblatt 高血压大鼠并无降压作用;当它确实降低血压时,其降压作用似乎与其抑制肾素的作用有关。此外,普萘洛尔可减轻高血压诱导的心脏肥大,且与其降压作用无关。